The non-dilutive funding will support Phase 2 clinical trials, in France and Europe, of the Company's lead asset, IGX12. Florent Ferré, Chief Executive Officer of Igyxos Biotherapeutics, said, "This funding marks another important new milestone in the clinical development of our innovative approach to treating infertility. Male infertility accounts for nearly half of all infertility cases and currently has no approved treatment. In the fourth quarter of 2025, Igyxos expects the latest results from its Phase 1 clinical trial in healthy volunteers. About Igyxos BiotherapeuticsIgyxos Biotherapeutics is dedicated to developing innovative treatments for infertility in both men and women.